DEA is Mismanaging the Marijuana Registration Process as UMISS is Still the Only Provider
WAHINGTON, DC / ACCESSWIRE / November 1, 2023 / As the DEA continues to play their callous, cruel, and indifferent game play in violation of President Biden's Marijuana Research and Expansion Act, Attorney Megan Sheehan representing MMJ International Holdings, MMJ BioPharma Cultivation, and MMJ BioPharma Labs is awaiting the DC appellate courts decision this week .
The DEA administration states," the DEA anticipates that additional strains of marihuana will be produced and made available to researchers. This should facilitate research, advance scientific understanding about the effects of marihuana, and potentially aid in the development of safe and effective drug products that may be approved for marketing by the Food and Drug Administration," however talk is cheap .
The DEA is Perpetuating a Ruse on the American Public
When looking at the already DEA approved API Bulk Manufactures none are growing the amount of marijuana necessary to meet the needs of the US researchers, none are conducting FDA approved clinical trials, and none are manufacturing a pharmaceutical with the exception of MMJ Companies .
The DEA mismanagement of the federal marijuana program is appalling. Sources have confirmed that registrations have been issued to:
Bright Green Corporation, a publicly traded company claiming to be the largest grower with no marijuana plants currently growing . Royal Emerald Pharmaceutical obtained a shipment of 22 cannabis plants from Celadon Pharmaceutical UK with all plants arriving dead . Currently Royal Emerald is growing 8 plants in their 100,000 square ft. facility in Desert Hot Springs, California. Scottsdale Research also growing minimal plants in a garage and on and on the litany of DEA mismanagement continues .
MMJ Companies, the premier medical cannabis development and research group announced that it has completed the FDA required manufacturing of its proprietary THC and CBD soft gel capsule medicine. MMJ has developed a dose form, non-synthetic oral drug product from the marijuana plant extracts. MMJ will be utilizing its new product for an FDA-approved treatment of Multiple Sclerosis (MS), and Huntington's disease (HD) for its clinical trials once approved.
Duane Boise the companies President stated "As the MMJ companies continue to overcome their struggle with the DEA's unexplained and unanswered delay, the issue is why has the DEA failed its legislative mandate? The DEA's incomprehensible actions are denying suffering patients from potential relief from the many benefits that cannabis will offer."
Dr Elio Mariani the company CEO lamented "talk is cheap and we are watching the inaction of the DEA". He further stated " We will get to the bottom of this at all cost. "
Congressman Buddy Carter recently slammed the DEA at a congressional hearing calling the agency the "EPITOME OF INEPTITUDE" he continued stating "as a practicing pharmacist for many years the worse thing for me to do is to fill a prescription for someone that doesn't need it however if they do need it I want to fill the prescription. If marijuana truly has medical benefit I want to know".
Listening to the congressman one can recognize that he has clearly defined the WHAT. The only remaining question is WHY?
Is the DEA acting intentionally? Does the DEA have a hidden agenda? Is the DEA personnel incompetent or merely under staffed? Or all of the above.
Millions of Americans depend on the DEA for their well being and they not only deserve an answer they demand an answer.
MMJ is represented by Attorney Megan Sheehan of Rhode Island.
For more information on MMJ, please visit www.mmjih.com.
Contact: MMJ
Madison Hisey
Email: mhisey@mmjih.com
203-231-8583
SOURCE: MMJ International Holdings